These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 16231237)
1. [Practical ambulatory therapy for multisystem atrophy and diabetes mellitus]. Fassbender WJ Dtsch Med Wochenschr; 2005 Oct; 130(41):2347-8. PubMed ID: 16231237 [No Abstract] [Full Text] [Related]
2. Initial management of glycemia in type 2 diabetes. Banarer S N Engl J Med; 2003 Feb; 348(8):760-1; author reply 760-1. PubMed ID: 12594327 [No Abstract] [Full Text] [Related]
3. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted? Standl E; Schnell O Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474 [No Abstract] [Full Text] [Related]
4. Successful treatment of markedly symptomatic patients with type II diabetes mellitus using high doses of sulfonylurea agents. Davidson MB West J Med; 1992 Aug; 157(2):199-200. PubMed ID: 1441492 [No Abstract] [Full Text] [Related]
5. [Type 2 diabetes: practical guide for starting ambulatory insulin therapy]. Pernet A; Gheno N Rev Med Suisse; 2006 May; 2(68):1453-4, 1456-8,1460-1. PubMed ID: 16783990 [TBL] [Abstract][Full Text] [Related]
6. Optimizing insulin therapy in patients with type 1 and type 2 diabetes mellitus: optimal dosing and timing in the outpatient setting. Hahr AJ; Molitch ME Am J Ther; 2008; 15(6):543-50. PubMed ID: 19127139 [TBL] [Abstract][Full Text] [Related]
7. Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes. Inzucchi SE Endocrinol Metab Clin North Am; 2007 Dec; 36 Suppl 2 Incretin():2-17. PubMed ID: 18405144 [No Abstract] [Full Text] [Related]
8. [Pharmacologic treatment of diabetes]. De Montigny P; Clerc C; Descarpentries C Perspect Infirm; 2006; 4(2):30-4. PubMed ID: 17184094 [No Abstract] [Full Text] [Related]
9. Drugs for type 2 diabetes. Treat Guidel Med Lett; 2008 Jul; 6(71):47-54. PubMed ID: 18583949 [No Abstract] [Full Text] [Related]
10. Insulin analogue usage in a haemodialysis patient with type 2 diabetes mellitus. Ersoy A; Ersoy C; Altinay T Nephrol Dial Transplant; 2006 Feb; 21(2):553-4. PubMed ID: 16221693 [No Abstract] [Full Text] [Related]
11. Glycaemic control in type 2 diabetes. Campbell A Clin Evid; 2005 Dec; (14):474-90. PubMed ID: 16620416 [No Abstract] [Full Text] [Related]
12. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Goldberg RB; Fonseca VA; Truitt KE; Jones MR Arch Intern Med; 2008 Jul; 168(14):1531-40. PubMed ID: 18663165 [TBL] [Abstract][Full Text] [Related]
13. A case of new mutation in maturity-onset diabetes of the young type 3 (MODY 3) responsive to a low dose of sulphonylurea. Jesić MD; Sajić S; Jesić MM; Maringa M; Micić D; Necić S Diabetes Res Clin Pract; 2008 Jul; 81(1):e1-3. PubMed ID: 18433912 [TBL] [Abstract][Full Text] [Related]
14. Oral combination therapy with thiazolidinediones and sulfonylureas in type 2 diabetes. Charbonnel B Int J Clin Pract Suppl; 2007 Jun; (153):1-2. PubMed ID: 17594387 [No Abstract] [Full Text] [Related]
15. Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes. Raskin P Diabetes Metab Res Rev; 2008; 24(1):3-13. PubMed ID: 17968971 [TBL] [Abstract][Full Text] [Related]
16. Treatment of type 2 diabetes mellitus and the incretin system. Whitehill D S D Med; 2007 May; 60(5):197, 199. PubMed ID: 17694940 [No Abstract] [Full Text] [Related]
17. Optimizing antidiabetic treatment options for patients with type 2 diabetes mellitus and cardiovascular comorbidities. Malesker MA Pharmacotherapy; 2008 Feb; 28(2):193-206. PubMed ID: 18225965 [TBL] [Abstract][Full Text] [Related]
18. Follow-up of intensive glucose control in type 2 diabetes. Petrie JR N Engl J Med; 2009 Jan; 360(4):416-7; author reply 418. PubMed ID: 19172672 [No Abstract] [Full Text] [Related]
19. Follow-up of intensive glucose control in type 2 diabetes. Mühlhauser I N Engl J Med; 2009 Jan; 360(4):417; author reply 418. PubMed ID: 19172674 [No Abstract] [Full Text] [Related]
20. The therapeutic efficacy of rosiglitazone is enhanced in sulphonylurea-treated patients with type 2 diabetes. Itakura H; Abbasi F; Lamendola C; Basina M; Reaven G Diabetes Obes Metab; 2008 Aug; 10(8):685-7. PubMed ID: 18476981 [No Abstract] [Full Text] [Related] [Next] [New Search]